Literature DB >> 24758481

Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.

A C Kai1, C Flohr, C E Grattan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24758481     DOI： 10.1111/ced.12320

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  4 in total

Review 1.  Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.

Authors:  Michael D Tharp; Jonathan A Bernstein; Abhishek Kavati; Benjamin Ortiz; Karen MacDonald; Kris Denhaerynck; Ivo Abraham; Christopher S Lee
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

2.  Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.

Authors:  Yudi Chen; Miao Yu; Xiaojie Huang; Ping Tu; Peikun Shi; Marcus Maurer; Zuotao Zhao
Journal:  World Allergy Organ J       Date:  2021-01-05       Impact factor: 4.084

3.  Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome.

Authors:  Hermenio Lima; Melinda Gooderham; Jan Dutz; Charles Lynde; Hugo Chapdelaine; Anne Ellis; Martin Gilbert; Vincent Ho; Kim Papp; Yves Poulin; Gordon Sussman
Journal:  Allergy Asthma Clin Immunol       Date:  2017-08-24       Impact factor: 3.406

4.  Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab.

Authors:  Marianne de Brito; Gisela Huebner; DedeeF Murrell; Peter Bullpitt; Karin Hartmann
Journal:  Clin Transl Allergy       Date:  2018-09-21       Impact factor: 5.871
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.